Only a small percentage of older adults who are in the early stages of Alzheimer's disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer's disease.
Reviewed by Danielle Ellis, B.Sc.Aug 16 2023 The new research is published in the August 16, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. Clinical trial results for these drugs are only available in people in the early symptomatic stages of the disease, mild cognitive impairment or mild dementia due to Alzheimer's disease.
"There is hope that these new therapies for Alzheimer's may slow progression of the disease for many people, although the fact remains that the drugs have only been studied in people with the earliest forms of the disease," said study author Maria Vassilaki, MD, PhD, of the Mayo Clinic in Rochester, Minnesota, and a member of the American Academy of Neurology.
For lecanemab, clinical trial inclusion criteria required specific scores on a variety of thinking and memory tests, as well as a body mass index between 17 and 35. Researchers found 112 people, or 47%, would meet the inclusion criteria to participate in a clinical trial.
For aducanumab, clinical trial inclusion criteria required specific scores on thinking and memory tests and that participants were ages 50 to 85. Researchers found 104 people, or 44%, would have met the characteristics required to participate in a clinical trial.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Charity art sale organiser shares heartbreaking story behind choosing Alzheimer's Society as beneficiaryOne of the organisers of a unique charity art sale has spoken of the devastating impact dementia has had on her family.
Read more »
Androgen deprivation therapy increases the risk of depression, dementia, Alzheimer’s disease, and Parkinson’s diseaseThe association between Androgen Deprivation Therapy (ADT) and the risk of dementia.
Read more »
Multimodal intervention approach shows promise in managing and reversing cognitive impairmentDr. Heather Sandison, a leading expert in Alzheimer's Disease and Related Dementia (ADRD) care, has recently published a groundbreaking study in the Journal of Alzheimer's Disease, highlighting significant improvements in cognitive function among individuals with cognitive decline.
Read more »
Older adults with mild cognitive impairment may struggle with everyday decision-makingMild cognitive impairment (MCI) is a form of cognitive ability loss that can precede Alzheimer's disease or other types of dementia. People with MCI have some trouble with memory and thinking, but can largely lead independent lives.
Read more »
Robbie Williams feeling confident as small changes bring big benefits'I feel a lot more confident as a player and as a person.'
Read more »
Small crypto exchanges take advantage of Binance’s declineCompanies such as Huobi and KuCoin have increased market share this year
Read more »